Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 577 - 584 of 12008 results

MintzTech Connect Industry News: Spotlight on GUDEA
September 18, 2024| Article| Viewpoint

Massachusetts Paid Family and Medical Leave: “Topping Off” Benefits is Determined by Employer Policy
September 18, 2024| Blog| Viewpoint

The Massachusetts Supreme Judicial Court Clarifies Rules on Benefit Accrual During PFML
September 18, 2024| Blog| Viewpoint

Senators Urge FTC, DOJ to Investigate AI Models That Copy Third-Party Content — AI: The Washington Report
September 18, 2024| Article| Viewpoint

A New Age of Agency Rulemaking and Enforcement
September 18, 2024| Blog| Viewpoint

5 Reasons Bigger 401k Plans Are Better
September 17, 2024| News

Will Sustained Pressure on the 340B Program Finally Lead to Much Needed Reform?
September 17, 2024| Blog| Viewpoint

Caveat Employer: An Employee’s Off-Duty Social Media Posts Can Constitute Workplace Harassment
September 16, 2024| Blog| Viewpoint
News & Press Releases
Mintz advised The Eagle Leasing Company, a leading provider of portable storage containers, ground level offices, semi-trailers, and mobile office solutions, in its acquisition by Rent-A-Container (RAC), a portfolio company of Kinderhook Industries, LLC.
Mintz’s Life Sciences practice has been shortlisted in multiple categories for the 2025 LMG Life Sciences Americas Awards. The winners will be announced at an awards ceremony in New York on September 4. In the United States, Mintz was shortlisted in the “Venture Capital Firm of the Year” category. In Canada, Mintz was shortlisted in the “Financial & Corporate Firm of the Year” and “Patent Strategy Firm of the Year” categories.
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
